Drugs / Recombinant Human Adenovirus Type 5 Injection
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05928962 | Oct 2022 → Aug 2023 | melanoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Adenovirus Type 5 Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05928962 ↗ |